News 
Market Data 
Discover
Replies to post #293231 on Amarin Corp Plc (AMRN)
For his part, Cannon acknowledged that limited physician knowledge is a big factor in why more patients have yet to be prescribed icosapent ethyl. However, he added, “there are lots of barriers. Reminding physicians and simply awareness of the data is certainly the first step, and that used to be the basic one. But then in a busy clinic you have to have time to remember that this could be an intervention. . . . I think it kind of just gets lost in the shuffle of other things in healthcare that this has not been beaten into us.”
Additionally, insurance coverage can also factor into why patients don’t get this drug. “We have gotten sucker punched with PCSK9s and just about every other new medicine where you have to fill out a prior authorization half the time to get it,” Cannon said, adding that this paperwork can pose a barrier. “Then, once you get approval, there's the co-pay business. If you have a non-Medicare patient, then you have to remember to get the co-pay card from the company and make sure it works.”
